Cantor Fitzgerald raises Eli Lilly stock price target on guidance By Investing.com

Cantor Fitzgerald raised its price target on Eli Lilly to $1,230 from $1,205 while keeping an Overweight rating, citing strong Mounjaro adoption outside the U.S. and supportive early launch commentary on Foundayo. The firm lifted its 2026 EPS estimate to $37.50 versus company guidance of $35.50 to $37.00, with Lilly also reporting Q1 2026 EPS of $8.55 and revenue of $19.8 billion, both above consensus. Management raised full-year 2026 guidance by $2 billion in revenue to $82 billion-$85 billion and by $2.00 per share in EPS, reinforcing a positive outlook.

Analysis

The market is still underestimating how much operating leverage is embedded in LLY’s mix shift toward higher-volume obesity and diabetes therapies. A modest increase in top-line assumptions translating into a disproportionately larger EPS bump implies the company is still early in the margin-expansion phase, which matters because consensus will likely keep chasing estimates higher as ex-US penetration and launch data remain supportive. In that setup, the stock’s real driver over the next 1-2 quarters is not just absolute sales growth, but the cadence of revisions versus a premium multiple that is already pricing in category leadership.

The more interesting second-order effect is on NVO. If LLY’s oral launch proves merely steady rather than explosive, that is still enough to keep the market focused on relative share, but not enough to force a wholesale rerating of the competitive landscape. That creates a window where NVO can lag on sentiment even if the GLP-1 category remains healthy, because investors will increasingly compare launch velocity, supply normalization, and promotional intensity rather than category growth alone.

The main risk to this bullish setup is a deceleration in U.S. prescription momentum after the initial novelty window, especially if payer friction or sequencing into the broader commercial channel slows uptake into late Q3. Another risk is that the market may be too comfortable extrapolating guidance upside into 2026 and 2027 before manufacturing, pricing, or competitive dynamics tighten. If launch commentary or ex-US demand merely meets expectations instead of beating them, the stock can still work, but the multiple likely stalls first.

Contrarian view: the consensus may be focusing too much on the guidance raise and not enough on how much of the upside is now becoming visible and thus monetized. That lowers asymmetry at the current price unless future revisions keep arriving every quarter. The best risk/reward may therefore be in relative trades rather than outright longs, using LLY strength to finance a cautious short or underweight in NVO if the market starts rewarding execution dispersion over sector beta.

Key Decisions for Investors

• Stay long LLY into the next 1-2 earnings cycles, but size for a lower convexity profile: upside is likely driven by estimate revisions rather than multiple expansion; use dips only if the market overreacts to any mid-quarter launch noise.
• Pair trade: long LLY / short NVO over the next 3-6 months. The trade monetizes execution dispersion in obesity franchise rollout and should work as long as LLY keeps printing revision upside while NVO remains a relative laggard on sentiment.
• Buy LLY call spreads 3-6 months out to capture another earnings-guidance reset while limiting premium paid; risk/reward is best if the market keeps rewarding incremental estimate raises rather than a sustained re-rating.
• If LLY rallies sharply on launch enthusiasm, trim into strength rather than chase: the stock’s absolute quality is high, but near-term returns may compress if the market starts pricing a flawless 2026 path.
• Set a trigger to reassess the long if late-Q3 prescription momentum slows or if ex-US growth no longer offsets U.S. launch maturation; that would signal the revision cycle is peaking sooner than expected.